Opendata, web and dolomites


Re-emerging Magic Molecules: The Medicalization of Psychedelics in the United States

Total Cost €


EC-Contrib. €






 ReMedPsy project word cloud

Explore the words cloud of the ReMedPsy project. It provides you a very rough idea of what is the project "ReMedPsy" about.

culture    interplay    insights    training    psychedelics    medicines    indicated    molecules    imaginaries    almost    forefront    psilocybin    psychiatric    risk    slowly    nor    addiction    depression    classifications    mental    health    policy    career    licensed    yield    scientists    actor    responsible    public    psychedelic    treating    drug    investigates    complete    methodology    center    political    1930s    introduction    society    actors    ketamine    model    abuse    sts    transfer    explores    regard    fostered    controversial    ascribing    governments    regulations    enabled    frame    again    country    decades    re    restrictive    2000    sociotechnical    deepen    researcher    contemporary    science    1960s    threat    traces    socio    mdma    revival    category    placed    qualitative    constellations    substances    accepted    co    benefit    see    highlighting    changed    began    significantly    western    ptsd    policies    coming    integration    standstill    recommendations    scientific    lsd    evaluations    medical    60s   

Project "ReMedPsy" data sheet

The following table provides information about the project.


Organization address
city: WIEN
postcode: 1010

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 261˙208 €
 EC max contribution 261˙208 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT WIEN AT (WIEN) coordinator 261˙208.00


 Project objective

This proposal presents a research-via-training project that will transfer knowledge from the U.S. to Europe and allow the experienced researcher to deepen her study of (re-)emerging scientific fields to advance her career significantly. The project explores how scientists and other actors currently re-frame psychedelics in a scientific model to make them into licensed medicines. Since their introduction into Western science and culture (1930s-60s), psychedelic substances such as psilocybin or LSD have been highly controversial. Although early research indicated promising psychiatric applications, Western governments began to see psychedelics as a threat to public health in the 1960s and placed them into the most restrictive drug category, ascribing them a high potential for abuse and no currently accepted medical use. After coming to an almost complete standstill for several decades, psychedelic research is slowly re-emerging since 2000, highlighting again their potential for treating mental health issues such as addiction, depression, or PTSD. Since neither the molecules nor regulations have changed, this project investigates which socio-political conditions have enabled this revival (e.g., changes in the scientific or broader culture, risk-benefit evaluations). It traces how the responsible re-integration of psychedelics is fostered through the interplay of actor constellations, the production of scientific knowledge, and sociotechnical imaginaries. Using a qualitative research methodology and approaches from Science and Technology Studies (STS), it focuses on three molecules that are at the center of contemporary research in the U.S. (the country currently at the forefront of psychedelic research): MDMA, psilocybin, and ketamine. The project results will yield important insights into how psychedelic science and society are co-produced, and provide timely policy recommendations with regard to drug classifications, and drug and public health policies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REMEDPSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REMEDPSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

QoSIoTSmartCities (2019)

Quality of Service for the Internet of Things in Smart Cities via Predictive Networks

Read More  

FreeDigital (2019)

The impact of 'free' digital offers on individual behavior and its implications for consumer and data protection laws

Read More  

COMLIB (2019)

Communists into Liberals: The Transformation and Demise of the Left as Precursor to the Illiberal Turn in Poland

Read More  
lastchecktime (2020-10-22 18:28:22) correctly updated